Modulation of endothelial function in cardiovascular disease: a potential role for nifedipineLüSCHER, Thomas F.Drugs (Basel). 1997, Vol 53, issn 0012-6667, 49 p., SUP1Serial Issue

ACE Inhibition and Vascular Protection in HypertensionLüSCHER, Thomas F.Journal of cardiovascular pharmacology. Supplement. 1999, Vol 34, Num 1, 38 p.Conference Proceedings

Haemodynamics of the vessel wallLüSCHER, Thomas F; KUTRYK, M.Seminars in interventional cardiology. 1998, Vol 3, Num 1, issn 1084-2764, 51 p.Serial Issue

Endothelial function : General considerationsHALLER, H.Drugs (Basel). 1997, Vol 53, pp 1-10, issn 0012-6667, SUP1Article

Unexplored territories with calcium channel blockers: potential for the futureSEVER, Peter S; OPARIL, Suzanne; LüSCHER, Thomas F et al.Journal of cardiovascular pharmacology. Supplement. 1999, Vol 33, Num 2, 26 p.Conference Proceedings

Efficacy and safety of spirapril in mild-to-moderate hypertensionHAYDUK, K; KRAUL, H.Journal of cardiovascular pharmacology. Supplement. 1999, Vol 34, Num 1, pp S19-S23Conference Paper

Circadian variation in cardiovascular events and implications for therapy?MULCAHY, D.Journal of cardiovascular pharmacology. Supplement. 1999, Vol 34, Num 2, pp S3-S8Conference Paper

Positron emission tomography to assess the haemodynamics of the coronary circulationCAMICI, P. G.Seminars in interventional cardiology. 1998, Vol 3, Num 1, pp 31-38, issn 1084-2764Article

Role of nitrates for the therapy of coronary artery disease patients in the years beyond 2000DARIUS, H.Journal of cardiovascular pharmacology. Supplement. 1999, Vol 34, Num 2, pp S15-S20Conference Paper

Matching the Risk: CAD Therapy on TimeWILLICH, Stefan N; LüSCHER, Thomas F.Journal of cardiovascular pharmacology. Supplement. 1999, Vol 34, Num 2, 36 p.Conference Proceedings

From endothelial dysfunction to cardiovascular diseaseLüSCHER, Thomas F.Journal of cardiovascular pharmacology. Supplement. 1998, Vol 32, Num 3, 82 p.Conference Proceedings

Inflammation in Coronary Artery Disease and Acute Myocardial Infarction - is the Stage Set for Novel Therapies? : Treatment of Atherosclerosis as an Inflammatory DiseaseKLINGENBERG, Roland; LÜSCHER, Thomas F.Current pharmaceutical design (Print). 2012, Vol 18, Num 28, pp 4358-4369, issn 1381-6128, 12 p.Article

Endothelins and endothelin receptor antagonists: Therapeutic considerations for a novel class of cardiovascular drugsLÜSCHER, Thomas F; BARTON, Matthias.Circulation (New York, N.Y.). 2000, Vol 102, Num 19, pp 2434-2440, issn 0009-7322Article

Clinical experience with spirapril in human hypertensionSCHMIDT, J; KRAUL, H.Journal of cardiovascular pharmacology. Supplement. 1999, Vol 34, Num 1, pp S25-S30Conference Paper

Coronary endothelial function in health and diseaseBURNETT, J. C.Drugs (Basel). 1997, Vol 53, pp 20-29, issn 0012-6667, SUP1Article

Proceedings of the meeting new insights and therapeutic strategies in cardiovascular disease: focus on endothelial targets, Venice, Italy, April 28-29, 2000PESSINA, Achille C; LüSCHER, Thomas F; ROSSI, Gian Paolo et al.Journal of cardiovascular pharmacology. Supplement. 2001, Vol 38, Num 2, 89 p.Conference Proceedings

Endothelial function and the kidney : An emerging target for cardiovascular therapyRABELINK, T. J; KOOMANS, H. A.Drugs (Basel). 1997, Vol 53, pp 11-19, issn 0012-6667, SUP1Article

Optimal nitrate therapy with a once-daily sustained-release formulation of isosorbide mononitrateWALLER, D. G.Journal of cardiovascular pharmacology. Supplement. 1999, Vol 34, Num 2, pp S21-S27Conference Paper

Endothelial dysfunction in cardiovascular disease : Risk factor, risk marker, or surrogate end point?ELLIOTT, H. L.Journal of cardiovascular pharmacology. Supplement. 1998, Vol 32, Num 3, pp S74-S77Conference Paper

The endothelium as prognostic factor and therapeutic target : What criteria should we apply?KAPLAN, N. M.Journal of cardiovascular pharmacology. Supplement. 1998, Vol 32, Num 3, pp S78-S80Conference Paper

Endothelial dysfunction and hypertensionFERRO, C. J; WEBB, D. J.Drugs (Basel). 1997, Vol 53, pp 30-41, issn 0012-6667, SUP1Article

ACE inhibition in chronic renal failure and in the treatment of diabetic nephropathy : Focus on spiraprilJARDINE, A. G; ELLIOTT, H. L.Journal of cardiovascular pharmacology. Supplement. 1999, Vol 34, Num 1, pp S31-S34Conference Paper

Angiotensin converting enzyme inhibitors and vascular protection in hypertensionRUSCHITZKA, F; NOLL, G; LÜSCHER, T. F et al.Journal of cardiovascular pharmacology. Supplement. 1999, Vol 34, Num 1, pp S3-S12Conference Paper

Testing Endothelial function using ultrasoundCELERMAJER, D. S.Journal of cardiovascular pharmacology. Supplement. 1998, Vol 32, Num 3, pp S29-S32Conference Paper

Endothelins and Cardiovascular Disease: Proceedings of a satellite symposium to the 17th Scientific Meeting of the International Society of Hypertension, Padua, Italy, June 12-13, 1998ROSSI, Gian Paolo; LüSCHER, Thomas F; PESSINA, Achille C et al.Journal of cardiovascular pharmacology. Supplement. 2000, Vol 35, Num 2, 86 p.Conference Proceedings